Author:
Dagogo-Jack Ibiayi,Kiedrowski Lesli A.,Lennerz Jochen K.
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference26 articles.
1. Dagogo-Jack I, Yoda S, Lennerz JK, et al. MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. Feb 2020;10.1158/1078-0432.CCR-19-3906.
2. Dagogo-Jack I. Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis. 2023.
3. Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of Acquired Resistance to Osimertinib in. Cancer Discov. 12 2018;8(12):1529-1539. 10.1158/2159-8290.CD-18-1022.
4. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. Apr 15 2013;19(8):2240-7. 10.1158/1078-0432.ccr-12-2246.
5. LV S, MJ A, JS L, et al. TATTON Phase Ib expansion cohort: osimertinib plus Savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKI). Annual meeting of the American Association for Cancer Research, Atlanta, GA 2019.2019.